The Efficacy and Safety of Telbivudine and Lamivudine Use in Highly Viremic Mothers to Prevent Hepatitis B Transmission
Phase of Trial: Phase IV
Latest Information Update: 01 Aug 2014
At a glance
- Drugs Lamivudine (Primary) ; Telbivudine (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Feb 2013 Planned End Date changed from 1 Jan 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.